PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27959445-0 2017 Delphinidin inhibits angiogenesis through the suppression of HIF-1alpha and VEGF expression in A549 lung cancer cells. delphinidin 0-11 vascular endothelial growth factor A Homo sapiens 76-80 26187071-8 2015 Combination of miR-137 mimics transfection and DPN treatment caused the highest inhibition of cell invasion and prevented angiogenic network formation due to the least expression of angiogenic factor (VEGF) in human glioblastoma cells in co-culture with human microvascular endothelial cells. delphinidin 47-50 vascular endothelial growth factor A Homo sapiens 201-205 24792670-0 2014 Delphinidin inhibits VEGF induced-mitochondrial biogenesis and Akt activation in endothelial cells. delphinidin 0-11 vascular endothelial growth factor A Homo sapiens 21-25 24792670-8 2014 In presence of delphinidin, VEGF failed to increase mitochondrial respiration, DNA content, complex IV activity and Akt activation in endothelial cells. delphinidin 15-26 vascular endothelial growth factor A Homo sapiens 28-32 24792670-9 2014 These results suggest a possible association between inhibition of VEGF-induced mitochondrial biogenesis through Akt pathway by delphinidin and its anti-angiogenic effect, providing a novel mechanism sustaining the beneficial effect of delphinidin against pathologies associated with excessive angiogenesis such as cancers. delphinidin 128-139 vascular endothelial growth factor A Homo sapiens 67-71 24792670-9 2014 These results suggest a possible association between inhibition of VEGF-induced mitochondrial biogenesis through Akt pathway by delphinidin and its anti-angiogenic effect, providing a novel mechanism sustaining the beneficial effect of delphinidin against pathologies associated with excessive angiogenesis such as cancers. delphinidin 236-247 vascular endothelial growth factor A Homo sapiens 67-71 16921400-0 2006 Delphinidin and cyanidin inhibit PDGF(AB)-induced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK. delphinidin 0-11 vascular endothelial growth factor A Homo sapiens 50-54 16921400-5 2006 KEY RESULTS: The inhibitory effect of RWPs on PDGF(AB)-induced release of VEGF was mimicked by delphinidin but not by quercetin, catechins, resveratrol, gallic acid or caffeic acid. delphinidin 95-106 vascular endothelial growth factor A Homo sapiens 74-78 16921400-6 2006 In the anthocyanin class, not only delphinidin but also cyanidin prevented VEGF release whereas malvidin and peonidin were without effect. delphinidin 35-46 vascular endothelial growth factor A Homo sapiens 75-79 16921400-9 2006 Although the p38 MAPK, ERK1/2 and JNK pathways have been involved in the PDGF(AB)-induced expression of VEGF, in our experiments, only phosphorylation of p38 MAPK and JNK was inhibited by RWPs, delphinidin and cyanidin. delphinidin 194-205 vascular endothelial growth factor A Homo sapiens 104-108 16308314-4 2006 In vitro, low concentrations of delphinidin inhibited vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor (VEGFR)-2, leading to the inhibition of downstream signaling triggered by VEGFR-2. delphinidin 32-43 vascular endothelial growth factor A Homo sapiens 54-88 16308314-4 2006 In vitro, low concentrations of delphinidin inhibited vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor (VEGFR)-2, leading to the inhibition of downstream signaling triggered by VEGFR-2. delphinidin 32-43 vascular endothelial growth factor A Homo sapiens 90-94 16308314-5 2006 Inhibition of VEGFR-2 by delphinidin inhibited the VEGF-induced activation of ERK-1/2 signaling and the chemotactic motility of human EC as well as their differentiation into capillary-like tubular structures in Matrigel and within fibrin gels. delphinidin 25-36 vascular endothelial growth factor A Homo sapiens 14-18 16308314-7 2006 The identification of delphinidin as a naturally occurring inhibitor of VEGF receptors suggests that this molecule possesses important antiangiogenic properties that may be helpful for the prevention and treatment of cancer. delphinidin 22-33 vascular endothelial growth factor A Homo sapiens 72-76 24124611-7 2013 Furthermore, in athymic nude mice subcutaneously implanted with human NSCLC cells, delphinidin treatment caused a (i) significant inhibition of tumor growth, (ii) decrease in the expression of markers for cell proliferation (Ki67 and PCNA) and angiogenesis (CD31 and VEGF), and (iii) induction of apoptosis, when compared with control mice. delphinidin 83-94 vascular endothelial growth factor A Homo sapiens 267-271 12909331-4 2003 METHODS AND RESULTS: Vascular endothelial growth factor-stimulated human umbilical endothelial cell migration and proliferation are potently inhibited by delphinidin. delphinidin 154-165 vascular endothelial growth factor A Homo sapiens 21-55 12909331-6 2003 Western blot analysis shows that delphinidin reverses the vascular endothelial growth factor-induced decrease in expression of cyclin-dependent kinase inhibitor p27(kip1) and the vascular endothelial growth factor-induced increase of cyclin D1 and cyclin A, both being necessary to achieve the G(1)-to-S transition. delphinidin 33-44 vascular endothelial growth factor A Homo sapiens 58-92 12909331-6 2003 Western blot analysis shows that delphinidin reverses the vascular endothelial growth factor-induced decrease in expression of cyclin-dependent kinase inhibitor p27(kip1) and the vascular endothelial growth factor-induced increase of cyclin D1 and cyclin A, both being necessary to achieve the G(1)-to-S transition. delphinidin 33-44 vascular endothelial growth factor A Homo sapiens 179-213 27959445-2 2017 In the present study, we investigated the inhibitory effects of delphinidin on vascular endothelial growth factor (VEGF) expression, an important factor involved in angiogenesis and tumor progression, in A549 human lung cancer cells. delphinidin 64-75 vascular endothelial growth factor A Homo sapiens 79-113 27959445-2 2017 In the present study, we investigated the inhibitory effects of delphinidin on vascular endothelial growth factor (VEGF) expression, an important factor involved in angiogenesis and tumor progression, in A549 human lung cancer cells. delphinidin 64-75 vascular endothelial growth factor A Homo sapiens 115-119 27959445-3 2017 Delphinidin inhibited CoCl2- and epidermal growth factor (EGF)-induced VEGF mRNA expression and VEGF protein production. delphinidin 0-11 vascular endothelial growth factor A Homo sapiens 71-75 27959445-3 2017 Delphinidin inhibited CoCl2- and epidermal growth factor (EGF)-induced VEGF mRNA expression and VEGF protein production. delphinidin 0-11 vascular endothelial growth factor A Homo sapiens 96-100 27959445-4 2017 Delphinidin also decreased CoCl2- and EGF-stimulated expression of hypoxia-inducible factor (HIF)-1alpha, which is a transcription factor of VEGF. delphinidin 0-11 vascular endothelial growth factor A Homo sapiens 141-145 27959445-5 2017 Delphinidin suppressed CoCl2- and EGF-induced hypoxia-response element (HRE) promoter activity, suggesting that the inhibitory effects of delphinidin on VEGF expression are caused by the suppression of the binding of HIF-1 to the HRE promoter. delphinidin 138-149 vascular endothelial growth factor A Homo sapiens 153-157 27959445-8 2017 Therefore, our results indicate that delphinidin has a potentially new role in anti-angiogenic action by inhibiting HIF-1alpha and VEGF expression. delphinidin 37-48 vascular endothelial growth factor A Homo sapiens 131-135